Rare Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Rare
| Protocol | Alliance A021804 |
|---|---|
| Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
| Protocol | SWOG S2012 |
|---|---|
| Cancer Type: | RARE |
RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAY191 - A3 |
|---|---|
| Cancer Type: | Rare Cancer |
| Fast Facts |
A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAY191 - N2 |
|---|---|
| Cancer Type: | Rare Cancer |
| Fast Facts |
PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EAY191 - N4 |
|---|---|
| Cancer Type: | Rare Cancer |
A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS
| Protocol | EAY191 - S3 |
|---|---|
| Cancer Type: | Rare Cancer |
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors
| Protocol | EAY191 - E5 |
|---|---|
| Cancer Type: | Rare Cancer |
A Randomized Phase II Study of AMG 510 (Sotorasib) with or without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1922 |
|---|---|
| Cancer Type: | Small bowel Adenocarcinoma |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
| Protocol | EAY191 - A6 |
|---|---|
| Cancer Type: | Rare Cancer |
A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS
Please check out the rare protocol list to locate other studies within this disease site.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | NRG HN010 |
|---|---|
| Cancer Type: | RARE |
A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A092001 |
|---|---|
| Cancer Type: | RARE |
PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA
| Protocol | SWOG S1900K |
|---|---|
| Cancer Type: | Rare Cancer |
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
| Protocol | SWOG S1900G |
|---|---|
| Cancer Type: | Rare Cancer |
A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
